Payment overview · 2025
General Payments
$2,363.78
83 reported records · 13 companies
Healthcare provider profile · identity verified
Kuldeep Singh Talwar, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · CYPRESS, TX · NPI 1225020522
Verified facts
What the public records show
CMS Open Payments records show Kuldeep Singh Talwar, MD received $2,363.78 in general payments during 2025 across 83 reported records.
Biosense Webster, Inc. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $698.65 | 29.6% | 21 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $507.95 | 21.5% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$286.71 | 12.1% | 18 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $232.09 | 9.8% | 9 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $169.82 | 7.2% | 10 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $122.00 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.89 | 4.2% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $93.94 | 4.0% | 3 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $83.74 | 3.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.60 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.82 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.88 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.69 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,363.78 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $654.89 | 20 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $257.59 | 3 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $228.30 | 9 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $124.47 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $122.00 | 1 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $122.00 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $122.00 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $118.11 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.89 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $93.94 | 3 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $93.53 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $93.05 | 8 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $83.74 | 3 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $52.43 | 6 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $51.71 | 3 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $51.43 | 5 | 2025 |
Source payment records
|
|||||
| QDOT MICRO Normalized: qdot micro |
Device | Biosense Webster, Inc. | $43.76 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $38.66 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $31.29 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| SELECTSECURE Normalized: selectsecure |
Device | Medtronic, Inc. | $17.41 | 2 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 394 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
394 | 122 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
394 | 122 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 424 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 420 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 135 |
| Eliquis | Apixaban | 394 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 338 | 117 |
| Carvedilol | Carvedilol | 325 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 107 |
| Furosemide | Furosemide | 255 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 73 |
| Amiodarone Hcl | Amiodarone Hcl | 205 | 85 |
| Lisinopril | Lisinopril | 174 | 54 |
| Losartan Potassium | Losartan Potassium | 170 | 55 |
| Potassium Chloride | Potassium Chloride | 165 | 57 |
| Sotalol | Sotalol Hcl | 161 | 43 |
| Xarelto | Rivaroxaban | 145 | 38 |
| Entresto | Sacubitril/Valsartan | 144 | 35 |
| Valsartan | Valsartan | 116 | 45 |
| Prasugrel Hcl | Prasugrel Hcl | 112 | 40 |
| Diltiazem Hcl | Diltiazem Hcl | 103 | 40 |
| Spironolactone | Spironolactone | 94 | 31 |
| Ezetimibe | Ezetimibe | 91 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 42 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 20 |
| Farxiga | Dapagliflozin Propanediol | 59 | 18 |
| Dofetilide | Dofetilide | 58 | 12 |
| Multaq | Dronedarone Hcl | 56 | 11 |
| Atenolol | Atenolol | 55 | 18 |
| Clonidine Hcl | Clonidine Hcl | 55 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 19 |
| Brilinta | Ticagrelor | 51 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 17 |
| Flecainide Acetate | Flecainide Acetate | 48 | 19 |
| Torsemide | Torsemide | 47 | 13 |
| Metformin Hcl | Metformin Hcl | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 12 |
| Midodrine Hcl | Midodrine Hcl | 37 | 18 |
| Irbesartan | Irbesartan | 36 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Digoxin | Digoxin | 34 | 15 |
| Chlorthalidone | Chlorthalidone | 33 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 32 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Eplerenone | Eplerenone | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Sotalol Af | Sotalol Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 19 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Corlanor | Ivabradine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | 13 |
| Cephalexin | Cephalexin | 13 | 12 |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,363.78 · 83 records | Biosense Webster, Inc. | ANGIO-SEAL, AVEIR, AVVIGO Guidance System, CAMZYOS, CARDIOMEMS, CARDIVA VASCADE 6/7F VCS, CARTO 3, COBALT DR MRI SURESCAN, ELIQUIS, ENSITE PRECISION, FARAPULSE, GLIDESHEATH SLENDER, General - Structural Heart, JARDIANCE, Kerendia, LINQ II, MICRA, MYNX CONTROL, MYNX CONTROL VENOUS, QDOT MICRO, REPATHA, SELECTSECURE, SYMPHONY CATHETER, SYMPLICITY G3, TR BAND, VersaCross Access Solution | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error